Convergent Hybrid Ablation Versus Catheter Ablation in Patients With Persistent Atrial Fibrillation and Heart Failure: HALT AF Study Protocol and Rationale for a Multicenter Randomized Controlled Trial
Top Cited Papers
Open Access
- 2 June 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e047774
Abstract
Background: The coexistence of persistent atrial fibrillation (AF) and heart failure with reduced left ventricular ejection fraction is associated with greater morbidity and death than either condition alone. Catheter ablation improves outcomes in selected patients, yet results in persistent AF remain unsatisfactory. Convergent hybrid ablation may offer more durable rhythm control by integrating epicardial and endocardial techniques to achieve homogeneous, transmural pulmonary vein and posterior wall isolation. However, randomized data comparing ablation strategies in patients with reduced left ventricular ejection fraction are lacking, leaving a critical evidence gap. Methods: HALT AF (Hybrid Ablation for Atrial Fibrillation With Heart Failure) is an investigator‐initiated, multicenter, prospective, open‐label, randomized controlled trial with blinded outcome assessment. A total of 120 patients with nonparoxysmal AF, left ventricular ejection fraction 30 seconds at 12 months and off class I/III antiarrhythmic drugs, excluding a 3‐month blanking period. The primary safety end point is major adverse cardiovascular events within 30 days. Secondary end points assess cardiac remodeling, biomarkers, symptoms, and quality of life. Conclusions: HALT AF will be the first randomized trial to compare convergent hybrid ablation and catheter ablation in patients with persistent AF and reduced left ventricular function. By enrolling only patients with reduced left ventricular ejection fraction and dilated atria and by equating lesion sets, HALT AF is designed to provide critical evidence to inform rhythm‐control strategies and guideline recommendations in this high‐risk, underrepresented population. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05411614.Keywords
This publication has 76 references indexed in Scilit:
- Atrial Fibrillation in Heart Failure: Novel Insights, Challenges, and Treatment OpportunitiesCurrent Heart Failure Reports, 2024
- Efficacy of Catheter Ablation for Atrial Fibrillation in Heart Failure: A Meta-Analysis of Randomized Controlled TrialsESC Heart Failure, 2024
- Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial FibrillationJAMA, 2024
- Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial FibrillationJAMA, 2023
- Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial FibrillationJAMA, 2022
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Journal of Heart Failure, 2022
- Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial FibrillationJAMA, 2020
- The management of atrial fibrillation in heart failure: an expert panel consensusHeart Failure Reviews, 2020
- Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial FibrillationJAMA, 2019
- Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country studyQuality of Life Research, 2012